Sotorasib and other drugs comparison in treating non-small cell lung cancer

Abstract

KRAS G12C is associated with poor diagnosis in non-small cell lung cancer (NSCLC), and this mutation accounts for 14% of total lung adenocarcinomas. Sotorasib is a KRAS G12C inhibitor drug that selectively treats NSCLC with KRAS G12C mutation. Other target therapies are available to treat NSCLC, and how Sotorasib differs in drug performance compared to other targeted therapies are not fully understood. This literature review compared Sotorasib with other NSCLC targeted therapy drugs to discuss the efficacy, side effect, and resistance between Sotorasib and other drugs that target NSCLC. Overall, Sotorasib did not show a pharmaceutical development innovation as it does not show an advantage in efficacy, side effects, and resistance compared to other drugs. Through reviews, Sotorasib could involve in group treatment with ErbB inhibition drug to better enhance the resistance outcome of the drug. As the side effect of both drugs is all severe, the safety of the combination needs further experiments.